Polysaccharide Polymer Particles for Copper Binding in Wilson's Disease

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for Wilson's disease, such as low-molecular-weight chelators and zinc salts, are limited by severe side effects and inefficiencies in copper management, leading to toxic copper accumulation in the body, and there is a need for a safer, more effective method to prevent and mitigate the disease's consequences.

Innovation Solution

Development of polymer particles containing functional groups that selectively adsorb copper(II) ions in the digestive tract, preventing copper absorption and excretion while being non-toxic and non-absorbable, thereby shifting the copper balance towards excretion without causing adverse effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If low-molecular-weight chelators (penicillamine, triethylenetetramine, tetrathiomolybdate) are administered to reduce copper in the body, then copper excretion is increased, but severe side effects occur including myelosuppression, lupus, and myasthenia

Engineering Contradiction:
Improvecopper excretionVSAvoidside effects
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces polymer particles as an intermediary substance that selectively binds copper ions in the gastrointestinal tract. These particles act as a mediator between copper intake and systemic absorption, preventing copper from entering the bloodstream while allowing normal copper metabolism to proceed without the toxic side effects of traditional chelators.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the chemical and physical parameters of copper binding by using polymers with specific functional groups (carboxyl, hydroxyl, amino, carbonyl) that have different binding characteristics compared to traditional chelators. This parameter change allows selective binding of copper without disrupting other essential metal ions, thereby eliminating side effects while maintaining copper excretion.

Inventive Principle:
Principle #35Parameter changes

2Productivity

If zinc(II) salts are administered in high doses (up to 1200 mg per day) to block copper intake, then copper absorption from diet is reduced, but severe gastrointestinal symptoms occur and zinc intoxication ensues

Engineering Contradiction:
Improvecopper absorption blockageVSAvoidgastrointestinal symptoms and zinc intoxication
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The polymer particles serve as an intermediary that blocks copper absorption without requiring high doses of zinc. The particles selectively bind copper ions in the gastrointestinal tract through their functional groups, preventing copper from being absorbed while having minimal impact on zinc metabolism and causing no gastrointestinal side effects.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the mechanism of copper blockage from zinc-based competition to polymer-based selective binding. This parameter change allows effective copper absorption blockage at much lower doses, eliminating the gastrointestinal symptoms and zinc intoxication associated with high-dose zinc therapy.

Inventive Principle:
Principle #35Parameter changes

3Productivity

If copper-containing foods are omitted from the diet to reduce copper intake, then copper accumulation is reduced, but nutritional deficiency occurs since copper is ubiquitous in food

Engineering Contradiction:
Improvecopper accumulation reductionVSAvoidnutritional intake
Core Design Contradiction:
ProductivityVSQuantity of substance

Solution Approach 1:

The polymer particles act as an intermediary that selectively intercepts copper ions in the gastrointestinal tract without affecting other nutrients. This allows patients to maintain a normal, nutritious diet while the particles prevent copper from being absorbed, thereby reducing copper accumulation without causing nutritional deficiency.

Inventive Principle:
Principle #24Intermediary (Mediator)

4Productivity

If traditional chelating agents are used to increase copper urinary excretion, then copper is removed from the body, but essential elements are re-complexed and reabsorbed from the gastrointestinal tract

Engineering Contradiction:
Improvecopper urinary excretionVSAvoidelemental balance
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The polymer particles serve as a selective intermediary that binds copper ions in the gastrointestinal tract and prevents their re-absorption. Unlike traditional chelators that can re-complex essential elements, the polymer particles maintain selective binding for copper while allowing other essential elements to pass through unchanged, thereby ensuring reliable elemental balance while achieving copper excretion.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The polymer particles effectively capture and bind copper in the gastrointestinal tract, reducing copper absorption and re-deposition in organs, thereby mitigating Wilson's disease symptoms without the severe side effects associated with existing treatments, and are completely eliminated through stools, ensuring safety.

Implementation Method 1

polymer particles containing functional groups that selectively adsorb copper(II) ions in the digestive tract

Methodology Applied
Scientific EffectAdsorption: Adsorption

Data Source

PatentEP3370735B1Polysaccharide-based polymer and its use for the prevention and treatment of the wilson's disease
Publication Date: 2020.05.13 USTAV MAKROMOLEKULARNI CHEM ACAD VED CESKE REPUBLIKY PRAHA
  • EP3370735B1 patent drawingFigure 1
  • EP3370735B1 patent drawingFigure 2
  • EP3370735B1 patent drawingFigure 3

AI summary

Polysaccharide based polymer and its use for the prevention and treatment of the Wilson's disease The present invention relates to polysaccharide based polymers modified by cross-linking and copper-binding groups, which are suitable as preparations for peroral administration for use in prevention and/or treatment of Wilson's disease.